Download PDF
Zentralbl Gynakol 2006; 128(1): 11-17
DOI: 10.1055/s-2006-921345
Übersicht

© Georg Thieme Verlag Stuttgart · New York

Diagnostik und Therapie maligner Ovarialtumoren 2005: Die Empfehlungen der Kommission Ovar der AGO

Diagnosis and Treatment of Malignant Ovarian Tumors 2005: Recommendations of the Kommission Ovar of the AGOB. Schmalfeldt1 , A. du Bois2 , A. Burges2 , G. Emons2 , D. Fink2 , M. Gropp2 , A. Hasenburg2 , W. Jäger2 , R. Kimmig2 , M. Kiechle1 , F. Kommoss2 , R. Kreienberg2 , W. Kuhn2 , H.-J. Lück2 , W. Meier2 , K. Münstedt2 , O. Ortmann2 , J. Pfisterer2 , B. Richter2 , I. Runnebaum2 , W. Schröder2 , J. Sehouli2 , B. Tanner2 , U. Wagner2 , J. Weis3
  • 1Frauenklinik der Technischen Universität München, Ismaninger Str. 2, 81675 München
  • 2Mitglieder der Kommission Ovar der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO)
  • 3Klinik für Tumorbiologie Freiburg
Further Information

Publication History

Publication Date:
31 January 2006 (online)

    Permissions and Reprints

Zusammenfassung

Die Mitglieder der Kommission Ovar der Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) haben in einem Konsensusverfahren aktuelle Empfehlungen zu Diagnostik und Therapie der malignen Ovarialtumoren erarbeitet und diese mit Evidenzlevel (LoE) und Empfehlungsgrad (GoR) der Canadian Task Force for Preventive Health Care bewertet. Eine Kurzfassung dieser Leitlinien, die die wichtigsten Publikationen bis Juni 2005 berücksichtigt, wird im Folgenden dargestellt.

Abstract

Recommendations for diagnosis and treatment of malignant ovarian tumors with regard to the most recent data were worked out in a consensus process and valued by level of evidence (LoE) and grade of recommendation (GoR) of the Canadian Task Force for Preventive Health Care by the members of the Kommission Ovar der Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) in june 2005. A short version of these guidelines is presented.

Schlüsselwörter

Leitlinien - Therapie - maligne Ovarialtumoren - Kommission Ovar der AGO

Key words

guidelines - therapy - malignant ovarian tumors - commission Ovar the AGO

Literatur

  • 1 Antoniou A, Pharoah P D, Narod S. et al . Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.  Am J Hum Genet. 2003;  72 1117-1130
    CrossrefPubMedGoogle Scholar
  • 2 Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland .Krebs in Deutschland - Häufigkeiten und Trends. 4. Ausgabe, Saarbrücken 2004
    Google Scholar
  • 3 Bell D A, Longacre T A, Prat J, Kohn E C, Soslow R A, Ellenson L H, Malpica A, Stoler M H, Kurman R J. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.  Hum Pathol. 2004;  35 934-948
    CrossrefPubMedGoogle Scholar
  • 4 Bell R, Petticrew M, Luengo S, Sheldon T A. Screening for ovarian cancer: a Systematic review. Health Technology Assessment 2:2, Southampton 1998
    Google Scholar
  • 5 Du Bois A, Lück H J, Meier W, Adams H P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J. A randomized clinical trial of Cisplatin/Paclitaxel versus Carboplatin/Paclitaxel as first-line treatment of ovarian cancer.  J Natl Cancer Inst. 2003;  95 1320-1329
    CrossrefPubMedGoogle Scholar
  • 6 Du Bois A, Meier W, Lück H J, Emons G. et al . Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.  Annals of Oncology. 2002;  13 251-257
    PubMedGoogle Scholar
  • 7 Bristow R E, Tomacruz R S, Armstrong D K, Trimble E L, Montz F J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.  J Clin Oncol. 2002;  20 1248-1259
    CrossrefPubMedGoogle Scholar
  • 8 Van der Burg M E, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave A J, Nardi M, Renard J, Pecorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.  N Engl J Med. 1995;  332 629-634
    CrossrefPubMedGoogle Scholar
  • 9 Cramer D W, Hutchison G B, Welch W R, Scully R E, Knapp R C. Factors affecting the association of oral contraceptives and ovarian cancer.  N Engl J Med. 1982;  307 1047-1051
    PubMedGoogle Scholar
  • 10 Crawford S C, Vasey P A, Paul J, Hay A, Davis J A, Kaye S B. Scottish Gynaecologic Cancer Trals Group .Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. Proc Am Soc Clin Oncol 2005; #5003 Abstract
    Google Scholar
  • 11 Elit L, Bondy S J, Paszat L, Przybysz R, Levine M. Outcomes in surgery for ovarian cancer.  Gynecol Oncol. 2002;  87 260-267
    CrossrefPubMedGoogle Scholar
  • 12 Gordon A N, Fleagle J T, Guthrie D. et al . Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicn versus topotecan.  J Clin Oncol. 2001;  19 3312-3322
    PubMedGoogle Scholar
  • 13 Harter P, Breitbach G P, Tanner B, Sehouli J, Heilmann V, Lueck H J, Kuhn W, Wimberger P, Ortmann O, du Bois A. Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO Organkommission Ovar and the AGO Ovarian Cancer Study Group (AGO-OVAR). Proc Am Soc Clin Oncol 2005; #5004 Abstract
    Google Scholar
  • 14 International Collaborative Ovarian Neoplasm (ICON) Collaborators . International Collaborative Ovarian Neoplasm Trial-1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.  J Natl Cancer Inst. 2003;  95 125-132
    CrossrefPubMedGoogle Scholar
  • 15 The ICON and AGO Collaborators . Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.  The Lancet. 2003;  361 2099-2106
    CrossrefPubMedGoogle Scholar
  • 16 Kommission Ovar der AGO .Ovarialkarzinom State of the Art. Juni 2005. CD-ROM, (ISBN 3-00-016-495-2)
    Google Scholar
  • 17 Lecuru F, Desfeux P, Camatte S, Bissery A, Robin F, Blanc B, Querleu D. Stage I ovarian cancer: comparison of laparoscopy and laparotomy on staging and survival.  Eur J Gynaecol Oncol. 2004;  25 571-576
    PubMedGoogle Scholar
  • 18 Mateo R, Singh G, Jabbour N, Palmer S, Genyk Y, Roman L. Optimal cytoreduction after combined resection and radiofrequency ablation of hepatic metastases from recurrent malignant ovarian tumors.  Gynecol Oncol. 2005;  97 266-270
    CrossrefPubMedGoogle Scholar
  • 19 Negishi H, Takeda M, Fujimoto T, Todo Y, Ebina Y, Watari H, Yamamoto R, Minakami H, Sakuragi N. Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer.  Gynecol Oncol. 2004;  94 161-166
    CrossrefPubMedGoogle Scholar
  • 20 Benedetti-Panici P B, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S, Angioli R, Manci N, Scambia G, Dell'Anna T, Fossati R, Floriani I, Rossi R S, Grassi R, Favalli G, Raspagliesi F, Giannarelli D, Martella L, Mangioni C. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.  J Natl Cancer Inst. 2005;  97 560-566
    CrossrefPubMedGoogle Scholar
  • 21 Pfisterer J, Plante M, Vergote I, du Bois A, Eisenhauer E. for the AGO-OVAR, NCIC CTG & EORTC GCG . Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.  Int J Gynecol Cancer. 2005;  15 (Suppl 1) 36-41
    CrossrefPubMedGoogle Scholar
  • 22 Piccart M J, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy J A, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.  Int J Gynecol Cancer. 2003;  13 (Suppl 2) 144-148
    CrossrefPubMedGoogle Scholar
  • 23 Rose P G, Nerenstone S, Brady M F, Clarke-Pearson D, Olt G, Rubin S C, Moore D H, Small J M. Secondary surgical cytoreduction for advanced ovarian carcinoma.  N Engl J Med. 2004;  351 2489-2497
    CrossrefPubMedGoogle Scholar
  • 24 Rosen B, Kwon J, Fung Kee Fung M. et al . Systematic review of management options for women with a hereditary predisposition to ovarian cancer.  Gynecol Oncol. 2004;  93 280
    CrossrefPubMedGoogle Scholar
  • 25 Sandercock J, Parmar M KB, Torri V, Quian W. First-line treatment for advanced Ovarian cancer: paclitaxel, platinum and the evidence.  Br J Cancer. 2002;  87 815-824
    CrossrefPubMedGoogle Scholar
  • 26 Schumer S T, Cannistra S A. Granulosa cell tumor of the ovary.  J Clin Oncol. 2003;  21 1180-1189
    CrossrefPubMedGoogle Scholar
  • 27 Seidman J D, Soslow R A, Vang R. et al . Borderline ovarian tumors: Diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images.  Hum Pathol. 2004;  35 918-933
    CrossrefPubMedGoogle Scholar
  • 28 Tavassoli F A, Devilee P. World Health Organization Classification of Tumours .Pathology & Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon 2003
    Google Scholar
  • 29 Tingulstad S, Skjeldestad F E, Halvorsen T B, Hagen B. Survival and prognostic factors in patients with ovarian cancer.  Obstet Gynecol. 2003;  101 885-891
    CrossrefPubMedGoogle Scholar
  • 30 Trimbos J B, Vergote I, Bolis G, Vermorken J B, Mangioni C, Madronal C. et al . Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer - Adjuvant Chemotherapy in Ovarian Neoplasmn Trial.  J Natl Cancer Inst. 2003;  95 113-125
    CrossrefPubMedGoogle Scholar
  • 31 Vasey P A, Jayson G C, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye S B. Scottish Gynaecological Cancer Trials Group . Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.  J Natl Cancer Inst. 2004;  96 1682-1691
    CrossrefPubMedGoogle Scholar
  • 32 Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore M E, Kaern J, Verrelst H, Sjovall K, Timmerman D, Vandewalle J, Van Gramberen M, Trope C G. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.  Lancet. 2001;  357 176-182
    CrossrefPubMedGoogle Scholar
  • 33 Whittemore A S, Harris R, Itnyre J. Collaborative Ovarian Cancer Group . Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epihelial ovarian cancers in white women.  Am J Epidemiol. 1992;  136 1184-1203
    PubMedGoogle Scholar
  • 34 De Wit R, Roberts J T, Wilkinson P M, de Mulder P HM, Mead G M, Fossa S D, Cook P, de Prijck L, Stenning S, Collette L. Equivalence of Three or Four Cycles of Bleomycin, Etoposide and Cisplatin Chemotherapy and for a 3- or 5-Day Schedule in Good-Prognosis Germ Cell Cancer: A Randomized Study of the European Organization for Research and Treatment of Cancer Genitouinary Tract Cancer Cooperative Group and the Medical Research Council.  J Clin Oncol. 2001;  19 1629-1640
    PubMedGoogle Scholar
  • 35 Zanetta G, Chiari S, Rota S, Bratina G, Maneo A, Torri V, Mangioni C. Conservative surgery for stage I ovarian carcinoma in women of childbearing age.  Br J Obstet Gynaecol. 1997;  104 1030-1035
    PubMedGoogle Scholar

Prof. Dr. B. Schmalfeldt

Sprecherin der Kommission Ovar der AGO · Frauenklinik der Technischen Universität München

Ismaninger Str. 22

81675 München

Email: barbara.schmalfeldt@lrz.tum.de

      >